Novavax and Gavi settle over Covid-19 vaccine partnership dispute
Novavax and Gavi, the Vaccine Alliance, have reached a settlement on their partnership disagreement, with the vaccine manufacturer handing Gavi a total of $400 million through December 2028.
In the settlement, Novavax has agreed to pay $75 million to Gavi and will also make subsequent payments of $80 million each year through the end of 2028. These payments are due quarterly.
There is the option of a yearly “vaccine credit” worth $80 million, where Novavax’s annual payments can be reduced if Gavi accesses any of Novavax’s Gavi-funded vaccines for use in low-income and lower-middle-income territories.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
